CRINONE ® - Progesterone

CRINONE ® is a Progesterone based drug

THERAPEUTIC GROUP: Progestinic

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications CRINONE ® - Progesterone

CRINONE ® is a progesterone-based gel useful as an adjuvant in the lutein phase in case of infertility and as a support to in vitro fertilization, useful for the resolution of tubal or endometrial problems.

CRINONE ® action mechanism - Progesterone

CRINONE ® is a progesterone based gel, which guarantees the continued release of this hormone, thanks to the presence of polymers such as polycarbophyl able to adhere to the uterine mucosa and facilitate the release of progesterone.

Applied to the vaginal level, it allows the progesterone to accumulate mainly in the uterine area, reducing the first-pass metabolism, therefore the production of metabolites with collateral activity to the progestin.

The result of these properties is an action concentrated predominantly at the uterine level, which mediates the passage from the proliferative phase to the secretory phase of the endometrium, useful for receiving the formed embryo and facilitating its growth.

From the pharmacokinetic point of view instead, CRINONE ® allows the release of progesterone which reaches the maximum concentration equal to about 90 mg in 6 hours, and then gradually decreases until the halving of the doses which is observed in about 36 hours.

Studies carried out and clinical efficacy

1. VAGINAL GEL OR INTRAMUSCULAR INJECTION?

Interesting study that shows how of the 468 patients treated with progesterone to support the artificial fertilization phase, those treated with vaginal gel are more satisfied with the therapy, with equal results, compared to the intramuscular injection of progesterone.

2. EFFECTIVENESS OF THE COSOMMINISTRATION OF VAGINAL AND ORAL PROGESTERONE IN THE TREATMENT OF INFERTILITY

A study conducted on 370 women under the age of 45, in which the simultaneous administration of oral and vaginal progesterone ensured a reduction in the rate of abortion, while reducing the number of bleeding episodes. Combination therapy could therefore be more effective than monotherapy.

3. CRINONE AS A THERAPEUTIC OPTION FOR SECONDARY AMENORREAS

Progesterone-based gels such as Crinone have been used successfully in the treatment of secondary amenorrhea, ensuring good bleeding control and significantly improving the endometrial health observed through histological sections.

Method of use and dosage

CRINONE ® 8% vaginal gel, capable of releasing up to 90 mg of progesterone per dose:

progesterone should be taken at ovulation or between the eighteenth and twentieth day of the cycle.

In the case of in vitro fertilization, the intake of CRINONE ® should continue until complete placental autonomy, useful for inhibiting possible myometrial contractions and at the same time supporting the growth of the embryo.

Medical supervision is important both in the initial phase of treatment and in the subsequent period of administration.

Warnings CRINONE ® - Progesterone

CRINONE ® should be administered only after a careful medical examination to clarify the origin of the complained disorders.

Patients suffering from liver and kidney diseases, diabetes, hypertension and cardiovascular diseases, epilepsy and neurological pathologies should be supervised more carefully by medical personnel and monitored for the appearance of side effects.

In the latter case the doctor should decide for the possible suspension of therapy.

The presence of vitamin C among the excipients of CRINONE ® could be responsible for local side effects such as burning and mucosal irritation.

Some of the side effects complained of during progestin therapy, such as above all headache and sleepiness, could reduce the patient's perceptive abilities, making it dangerous to use machinery and vehicles.

PREGNANCY AND BREASTFEEDING

CRINONE ® can be used during the first trimester of pregnancy to compensate for functional deficiencies in the corpus luteum, which are subsequently replaced by the secretory activity of the placenta.

Its intake, on the other hand, is contraindicated during the period of breastfeeding, given the ability of progesterone to be secreted in breast milk, therefore assumed by the infant.

Interactions

Although CRINONE ® therapy minimizes potential interactions with other active ingredients, it should be avoided that this drug is administered with other products for vaginal use that can irritate the mucosa.

Contraindications CRINONE ® - Progesterone

CRINONE ® is contraindicated in case of hypersensitivity to the active ingredient or to one of its excipients, in case of vaginal bleeding of unknown origin, breast cancer or estrogen-progestin dependent tumors, changes in liver function and existing or previous thromboembolic processes.

Undesirable effects - Side effects

The vaginal administration of progesterone significantly reduces the appearance of both acute and chronic side effects, so as to preserve a good tolerability of CRINONE ® therapy

The most common side effects include headache, migraine, drowsiness, increased breast tension with related pain, vaginal spotting and local irritation.